Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

B. Chapman, Paul; Hauschild, Axel; Robert, Caroline; B.A.G. Haanen, John; A. Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbé, Célèste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O’Day, Steven; A. Sosman, Jeffrey; M. Kirkwood, John; M.M. Eggermont, Alexander; Dréno, Brigitte; B. Nolop, K.; Li, Jiang; Nelson, B.; Hou, Jeannie; J. Lee, Richard; T. Flaherty, Keith; A. McArthur, Grant

doi:10.1056/nejmoa1103782

Public

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Published in New England Journal of Medicine • Jun 5, 2011

Authors:

Paul B. Chapman

Axel Hauschild

Caroline Robert

Abstract

BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine ...

Subject

Vemurafenib

Medicine

Dacarbazine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!